

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**康宁杰瑞**

ALPHAMAB ONCOLOGY

**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 12, 2024**

Reference is made to the circular (the “**Circular**”) and the notice of the annual general meeting (the “**AGM**”) (the “**AGM Notice**”) of Alphamab Oncology (the “**Company**”) both dated May 21, 2024. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular and AGM Notice.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that at the AGM held on June 12, 2024, all proposed resolutions as set out in the AGM Notice were duly approved by the Shareholders by way of poll.

As at the date of the AGM, the total number of issued shares of the Company was 964,923,807 shares. No Shareholders were required under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) to abstain from voting on any of the resolutions at the AGM and no Shareholders were entitled to attend and abstain from voting in favor as set out in Rule 13.40 of the Listing Rules. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The Company’s share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

All the Directors, namely Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors attended the AGM in person or by electronic means.

The poll results in respect of each resolution proposed at the AGM were as follow:

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
1.	To consider and receive the audited consolidated financial statements of the Company and the reports of the Directors and the auditor of the Company for the year ended December 31, 2023	540,493,858 99.981502%	100,000 0.018498%
2.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding any shares that are held as treasury shares)	540,493,858 100.000000%	0 0.000000%
3.	To grant a general mandate to the Directors to allot, issue and deal with shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding any Shares that are held as treasury shares)	535,175,205 99.015964%	5,318,653 0.984036%
4.	To extend the general mandate granted to the Directors to issue shares of the Company by adding thereto the shares to be bought back by the Company	535,175,205 99.015964%	5,318,653 0.984036%
5.	(i) To re-elect Ms. LIU Yang as an executive Director	539,730,787 99.858820%	763,071 0.141180%
	(ii) To re-elect Dr. GUO Zijian as independent non-executive Director	540,412,687 99.984982%	81,171 0.015018%
6.	To authorise the Board to fix the remuneration of the Directors	540,335,438 99.970690%	158,420 0.029310%
7.	To re-appoint Messrs. Deloitte Touche Tohmatsu as auditors of the Company and authorise the Board to fix their remuneration	540,412,687 99.984982%	81,171 0.015018%
8.	To approve, confirm and adopt the proposed amendments to the post-IPO share option scheme of the Company adopted on May 25, 2020 and authorize the Directors to execute all such documents and do all such other acts and things as he/she/they may, in his/her/their absolute discretion, consider necessary, desirable or expedient to effect such amendments and any of the foregoing	535,686,405 99.110544%	4,807,453 0.889456%

ORDINARY RESOLUTIONS		No. of Votes (%)	
		For	Against
9.	To approve, confirm and adopt the proposed amendments to the restricted share award scheme of the Company adopted on March 31, 2021 and authorize the Directors to execute all such documents and do all such other acts and things as he/she/they may, in his/her/their absolute discretion, consider necessary, desirable or expedient to effect such amendments and any of the foregoing	535,686,405 99.110544%	4,807,453 0.889456%
10.	To approve and confirm the proposed refreshment of the Scheme Mandate Limit (as defined in the circular of the Company dated May 21, 2024) and authorize the directors of the Company to execute all such documents and do all such other acts and things as he/she/they may, in his/her/their absolute discretion, consider necessary, desirable or expedient to effect the Scheme Mandate Limit and any of the foregoing	535,686,405 99.110544%	4,807,453 0.889456%

*Note:* The full text of the above resolutions are set out in the AGM Notice.

As more than 50% of votes were cast in favour of the ordinary resolutions nos. 1 to 10 above, all such resolutions were duly passed by the Shareholders as ordinary resolutions.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, June 12, 2024

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.*